我們已在上線！進一步了解

Taro Pharmaceutical Industries Ltd.

TARO

市值 US$16.2億

已下市

TARO已於2024年6月21日下市。

返回排名列表

關於： Taro Pharmaceutical Industries Ltd produces, researches, develops, and markets pharmaceutical products. Its primary focus includes semi-solid formulations, such as creams and ointments, and other dosage forms such as liquids, capsules, and tablets. The company is engaged in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Israel, and Other Countries.

員工： 1,554

醫療保健藥品製造商－一般

新聞

正面

中性

負面

市場情緒 3個月

正面 0%

中性 0%

負面 0%

Taro Shareholders Approve Merger with Sun Pharma

MUMBAI, India and NEW YORK , May 23, 2024 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associates referred as "Sun Pharma") and Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") today announced that the merger agreement between Taro and Sun Pharma was approved by the affirmative vote of Taro shareholders (including a vote of the majority of shares held by Taro shareholders unaffiliated with Sun Pharma) at an Extraordinary General Meeting and an Ordinary Class Meeting on May 22, 2024.

Taro Shareholders Approve Merger with Sun Pharma

Taro Provides Results for Year Ended March 31, 2024

HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO PROVIDES RESULTS FOR YEAR ENDED MARCH 31, 2024.

Taro Provides Results for Year Ended March 31, 2024

Shareholder Alert: Ademi LLP investigates whether Taro Pharmaceutical Industries Limited has obtained a Fair Price for its Public Shareholders in its transaction with its majority shareholder, Sun Pharmaceutical Industries Limited.

MILWAUKEE , May 20, 2024 /PRNewswire/ -- Ademi LLP is investigating Taro (NYSE: TARO) for possible breaches of fiduciary duty and other violations of law in its transaction with its majority shareholder Sun. Click here to learn how to join the https://www.ademilaw.com/case/taro-pharmaceutical-industries-limited or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Taro Pharmaceutical Industries Limited has obtained a Fair Price for its Public Shareholders in its transaction with its majority shareholder, Sun Pharmaceutical Industries Limited.

Taro to Release Full Year Results on May 20, 2024

HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO TO RELEASE FULL YEAR RESULTS ON MAY 20, 2024.

Taro to Release Full Year Results on May 20, 2024

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Taro Shareholders Vote “FOR” Taro Sun Pharma Merger

NEW YORK--(BUSINESS WIRE)--Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Taro Shareholders Vote “FOR” Taro Sun Pharma Merger.

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Taro Shareholders Vote “FOR” Taro Sun Pharma Merger

TARO PHARMACEUTICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Taro Pharmaceutical Industries Ltd. - TARO

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Taro Pharmaceutical Industries Ltd. (NYSE: TARO) to Sun Pharmaceutical Industries Limited. Under the terms of the proposed transaction, shareholders of Taro will receive $43.00 in cash for each share of Taro that they own. KSF is seeking to determine whether this consideration and the process that led to it ar.

TARO PHARMACEUTICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Taro Pharmaceutical Industries Ltd. - TARO

Taro Announces Extraordinary General Meeting and Ordinary Class Meeting of Shareholders for Approval of Merger with Sun Pharmaceutical Industries Ltd.

NEW YORK--(BUSINESS WIRE)--Taro Announces Extraordinary General Meeting and Ordinary Class Meeting of Shareholders for Approval of Merger with Sun Pharmaceutical Industries Ltd.

Taro Announces Extraordinary General Meeting and Ordinary Class Meeting of Shareholders for Approval of Merger with Sun Pharmaceutical Industries Ltd.

TARO PHARMACEUTICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Taro Pharmaceutical Industries Ltd. - TARO

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Taro Pharmaceutical Industries Ltd. (NYSE: TARO) to Sun Pharmaceutical Industries Limited. Under the terms of the proposed transaction, shareholders of Taro will receive $43.00 in cash for each share of Taro that they own. KSF is seeking to determine whether this consideration and the process that led to it ar.

TARO PHARMACEUTICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Taro Pharmaceutical Industries Ltd. - TARO

Krensavage Asset Management Remains Opposed to Sun's Predatory Bid for Taro

NEW YORK , Jan. 30, 2024 /PRNewswire/ -- Krensavage Asset Management today sent the following message to a special committee evaluating Sun Pharmaceutical Industries Ltd.'s bid for Taro Pharmaceutical Industries Ltd.

Krensavage Asset Management Remains Opposed to Sun's Predatory Bid for Taro

Taro to Release Third Quarter Results on January 25, 2024

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro to Release Third Quarter Results on January 25, 2024.

Taro to Release Third Quarter Results on January 25, 2024

查看新聞排名

價格圖表採用Lightweight Charts™實作